Ocular hypotensive efficacy and safety of travoprost 0.004% in inadequately controlled primary open-angle glaucoma or ocular hypertension: short-term, multicenter, prospective study

References

• Coleman AL. Glaucoma. Lancet 1999;354:1803-10
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363:1711-20
   PubMed Web of Science ®Google Scholar
• The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-40
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hussein M, et al. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48-56
   Google Scholar
• Leske MC, Heijl A, Hyman L, et al. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol 2004;15:102-6
   PubMedGoogle Scholar
• Maier PC, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and primary open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 2005;331:134
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20
   PubMed Web of Science ®Google Scholar
• EGS. Terminology and guidelines for glaucoma, 2nd edn. Savona: Dogma ed., 2003
   Google Scholar
• Anton A. Should beta blockers be abandoned as initial monotherapy in chronic open angle glaucoma? View 1. Br J Ophthalmol 2002;86:692-3
   PubMed Web of Science ®Google Scholar
• Skuta GL. Should beta blockers be abandoned as initial monotherapy in chronic open angle glaucoma? View 2. Br J Ophthalmol 2002;86:693-4
   PubMed Web of Science ®Google Scholar
• Reiss GR, Brubaker RF. The mechanism of betaxolol, a new ocular hypotensive agent. Ophthalmology 1983;90:1369-72
   PubMed Web of Science ®Google Scholar
• Diggory P, Cassels-Brown A, Vail A, et al. Randomized, controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma. Br J Ophthalmol 1998;82:146-9
   PubMed Web of Science ®Google Scholar
• Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000;84:710-3
   PubMed Web of Science ®Google Scholar
• Yamada Y, Takayanagi R, Tsuchiya K, et al. Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists. J Ocul Pharmacol Ther 2001;17:235-48
   PubMed Web of Science ®Google Scholar
• Van der Valk R, Weber CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-85
   PubMed Web of Science ®Google Scholar
• Camras CB. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. Adv Prostaglandin Thromboxane Leukot Res 1995;23:519-25
   PubMedGoogle Scholar
• Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 2001;131:19-24
   PubMed Web of Science ®Google Scholar
• Li N, Chen X, Zhou Y, et al. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Experiment Ophthalmol 2006;34:755-64
   PubMed Web of Science ®Google Scholar
• Toris CB, Zhan G, Fan S, et al. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J Glaucoma 2007;16:189-95
   PubMed Web of Science ®Google Scholar
• Lim KS, Nau CB, O’Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. Ophthalmology 2008;115:790-5
   PubMed Web of Science ®Google Scholar
• Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84
   PubMed Web of Science ®Google Scholar
• Fellman RL, Sullivan EK, Ratliff M, et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology 2002;109:998-1008
   PubMed Web of Science ®Google Scholar
• Tielsch JM, Katz J, Sommer A, et al. Hypertension, perfusion pressure, and primary open-angle glaucoma: a population-based assessment. Arch Ophthalmol 1995;113:216-21
   PubMed Web of Science ®Google Scholar
• Leske MC, Connell MS, Wu SY, et al. Risk factors for open-angle glaucoma; The Barbados Eye Study. Arch Ophthalmol 1995;113:918-24
   PubMed Web of Science ®Google Scholar
• Bonomi L, Marchini G, Marraffa M, et al. Vascular risk factors for primary open-angle glaucoma: the Egna-Neumarkt Study. Ophthalmology 2000;107:1287-93
   PubMed Web of Science ®Google Scholar
• Quigley HA, West SK, Rodriguez J, et al. The prevalence of glaucoma in a population-based of Hispanic subjects. Proyecto VER. Arch Ophthalmol 2001;119:1819-26
   PubMed Web of Science ®Google Scholar
• Leske MC, Wu SY, Nemesure B, et al. Incident open-angle glaucoma and blood pressure. Arch Ophthalmol 2002;120:954-9
   PubMed Web of Science ®Google Scholar
• Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41:2566-73
   PubMed Web of Science ®Google Scholar
• Brusini P, Filacorda S. Enhanced Glaucoma Staging System (GSS 2) for classifying functional damage in glaucoma. J Glaucoma 2006;15:40-6
   PubMed Web of Science ®Google Scholar
• Cantor LB, Hoop J, Morgan L, et al. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol 2006;90:1370-3
   PubMed Web of Science ®Google Scholar
• Chiselita D, Antohi I, Medvichi R, et al. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Oftalmologia 2005;49:39-45
   PubMedGoogle Scholar
• Hepsen IF, Ozkaya E. 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension. Eye 2007;21:453-8
   PubMed Web of Science ®Google Scholar
• Orzalesi N, Rossetti L, Bottoli A, et al. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 2006;113:239-46
   PubMed Web of Science ®Google Scholar
• Stewart WC, Konstas AG, Nelson LA, et al. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 2008;115:1117-22
   PubMed Web of Science ®Google Scholar
• Racz P, Ruzsonyi MR, Nagy ZT, et al. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol 1996;114:268-73
   PubMed Web of Science ®Google Scholar
• Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 2004;26:84-91
   PubMed Web of Science ®Google Scholar
• Larsson LI, Mishima HK, Takamatsu M, et al. The effect of latanoprost on circadian intraocular pressure. Surv Ophthalmol 2002;47:S90-6
   PubMed Web of Science ®Google Scholar
• Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressure in the Advanced Glaucoma Intervention Study. Ophthalmology 2008;115:1123-9
   PubMedGoogle Scholar
• Hong S, Seong GJ, Hong YJ. Long-term intraocular pressure fluctuation and progressive visual field deterioration in patients with glaucoma and low intraocular pressure after a triple procedure. Arch Ophthalmol 2007;125:1010-3
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Weinreb RN, Zangwill LM, et al.Long-term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma. Ophthalmology 2008;115:934-40
   PubMedGoogle Scholar
• Bengtsson B, Leske MC, Hyman L, et al. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology 2007;114:205-9
   PubMed Web of Science ®Google Scholar
• Astin M, Stjernschantz J, Selen G. Role of nitric oxide in PGF2α-induced ocular hyperemia. Exp Eye Res 1994;59:401-7
   PubMed Web of Science ®Google Scholar
• Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 2007;16:98-103
   PubMed Web of Science ®Google Scholar
• Novack GD, O’Donnell MJ, Molloy DW. New glaucoma medications in the geriatric population: efficacy and safety. J Am Geriatric Soc 2002;50:956-62
   PubMed Web of Science ®Google Scholar